A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) - The ARREST-BP study for patients with Bullous Pemphigoid

Akari Therapeutics Plc0 个研究点目标入组 3 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

阶段: 3 期
状态: 撤回
发起方: Akari Therapeutics Plc
入组人数: 3

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1. Male or female between 18 and 89 years of age inclusive at the time of
•consent with Karnofsky score of 50% or more at screening.
•2. Male or female * 90 years of age at the time of consent with Karnofsky score
•of 70% or more at screening.
•3. Diagnosis of Bullous Pemphigoid (either newly diagnosed or relapsing); if
•relapsing they may have previously been shown to satisfy these diagnostic
•criteria for BP:
•a. blisters alone, or blisters and/or urticaria or papules or erythema with or
•without itch,
•b. direct immunofluorescence of perilesional skin collected near a fresh
•blister, erosion or papule showing linear deposition of immunoglobulin G (IgG)
•and/or C3 along the epidermal basement membrane zone,
•c. indirect immunofluorescence studies performed with patient serum on 1.0M
•NaCl human salt split skin, showing anti-basement membrane zone antibodies
•binding the epidermal side of the salt split skin OR anti-BP180 or anti-BP230
•antibody positive by enzyme linked immunosorbent assay. Note, if the serum
•binds both the epidermal and dermal side of the salt split skin the serum must
•also be anti-BP180/BP230 antibody positive by ELISA for inclusion of the
•4. Patients with atypical Bullous Pemphigoid (ie without blisters) if they have
•positive direct immunofluorescence AND positive indirect immunofluorescence AND
•are anti-BP180 antibody positive.
•5. Bullous Pemphigoid classified as either moderate or severe on the basis of
•the Investigator Global Assessment (IGA) at randomisation. Moderate BP
•classified as an IGA score of 3 and severe BP classified as an IGA score of 4.
•6. Willing to receive immunisation against Neisseria meningitidis and/or
•antibiotic prophylaxis in accordance with applicable guidelines and local
•standard of care (SOC).
•7. Ability to travel to site for scheduled clinic visits and be available for
•scheduled assessments to be performed in their place of residence by trained
•healthcare practitioners.
•8. Provision of voluntary written informed consent. Note: Consent must be
•obtained prior to any study-related procedures.
•9. Women of childbearing potential must agree to use two methods of
•contraception, one highly effective and one effective (barrier), consistently
•throughout the study and have a negative serum pregnancy test at screening and
•a negative urine pregnancy test per the schedule of events. Women are
•considered post-menopausal and not of childbearing potential if they have had
•12 months of amenorrhea, without an alternative medical cause, or have had
•permanent sterilisation methods (including hysterectomy, bilateral
•salpingectomy and bilateral oophorectomy) at least six weeks before
•randomisation.
•10. Males with a childbearing potential partner must agree to use two methods
•of contraception, one highly effective and one effective, consistently
•throughout the study including a barrier method.

排除标准

•1. Patients with recalcitrant BP that have never achieved CDA or who have never
•been in complete disease remission with persistent disease after a period of 12
•months from the start of super potent steroid or OCS treatment.
•2. Epidermolysis bullosa acquisita, mucous membrane pemphigoid, or anti p200
•pemphigoid.
•3. Mucosal lesion BPDAI score accounts for >or = 30% of total BPDAI activity
•score at randomisation.
•4. BP considered to be drug induced, in particular diagnosis of BP made within
•two months of starting a drug well known to induce BP * notably including, but
•not limited to, dipeptidyl peptidase-4 (DDP-4) inhibitor, anti-PD1 inhibitors,
•and certain diuretics and neuroleptics.
•5. Participation in a clinical trial of an investigational product within 6
•weeks of screening.
•6. Treatment with BP-directed biologics as follows:
•a. Any cell-depleting agents including, but not limited to, rituximab within 12
•months prior to baseline.
•b. Other biologics within five half-lives (if known) or 16 weeks prior to the
•baseline, whichever is longer.
•c. Intravenous immunoglobulin within 16 weeks prior to the baseline.
•7. Taking > 0.3 mg/kg/day OCS at screening.
•8. Treatment with systemic immunomodulators such as dapsone or doxycycline
•within four half-lives of the drugs prior to baseline Day 1 (5 days for
•dapsone, 3 days for doxycycline).
•9. Treatment with immunosuppressants (such as methotrexate, azathioprine,
•mycophenolate, calcineurin inhibitors) within the last two weeks prior to
•baseline (Day 1).
•10. Treatment with an anti-complement therapy or with Zileuton (Zyflo) within
•the last three months prior to baseline (Day 1).
•11. OCS dose no more than 0.3mg/kg/day in the 7 days before screening visit.
•12. Taking super-potent topical corticosteroids (such as clobetasol propionate,
•augmented betamethasone dipropionate, siflucortolone valerate, fluocinonide,
•flurandrenolide and halobetasol propionate) and unable to discontinue them at
•or before the screening assessment.
•13. Medical or surgical conditions at screening or Day 1, that in the
•Investigator's opinion would make the patient inappropriate for study entry;
•this might include severe medical conditions such as stroke, heart failure, or
•serious neoplasia with a very high risk of mortality.
•14. Impaired neurological function which, in the investigator*s opinion, will
•prevent participation in the study.
•15. Active systemic or organ system bacterial or fungal infection or
•progressive severe infection (including unresolved or untreated N. meningitidis
•infection and Escherichia coli Shiga toxin).
•16. Known congenital immunodeficiency or a history of acquired immunodeficiency
•including a positive human immunodeficiency virus (HIV) test.
•17. Active infection with hepatitis B or C.
•18. Positive nasal throat swab for Neisseria species.
•19. Planned major surgical procedures during the conduct of the study.
•20. Known hypersensitivity to nomacopan and any of its excipients.
•21. Contraindication to OCS including uncontrolled diabetes mellitus,
•uncontrolled hypertension, cardiac insufficiency, recent serious infection and
另有 4 项未显示

研究者

发起方

Akari Therapeutics Plc

相似试验

进行中（未招募）

1 期

A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tabletsmoderate to severe bullous pemphigoidMedDRA version: 21.1Level: LLTClassification code 10006567Term: Bullous pemphigoidSystem Organ Class: 100000004858

EUCTR2020-005987-67-DEAkari Therapeutics Plc48

进行中（未招募）

1 期

EUCTR2020-005987-67-NLAkari Therapeutics Plc48

进行中（未招募）

不适用

A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine in 18-55 year old healthy subjectsHealthy subjects - prevention of smallpox infectionMedDRA version: 8.0Level: PTClassification code 10041197

EUCTR2005-001781-14-DEBavarian Nordic A/S800

招募中

2 期

A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosisidiopathic pulmonary fibrosis

NL-OMON55928ovartis6

进行中（未招募）

1 期

Study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF)MedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic pulmonary fibrosis

EUCTR2021-005066-17-PLovartis Pharma AG94